Back to 
BlackRock, Inc.
BlackRock, Inc.
BCLI4 quarters
Position history for BlackRock, Inc.'s holdings in BrainStorm Cell Therapeutics In
No. BlackRock exited its BCLI (BrainStorm Cell Therapeutics in) position in Q3 2025. Its Q2 2025 13F listed 25,172 shares worth $28,193. BlackRock first reported BCLI in Q4 2024 and held it in 3 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$57,140
Total Shares Change
-25,172
Quarter-by-Quarter History
Other major holders of BCLI: VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, HRT FINANCIAL LP